Black Sabbath rebooks summer tour without Iommi

Although there was some hope that Black Sabbath guitarist Tony Iommi's lymphoma diagnosis would not disrupt the band's long-awaited reunion tour, according to their Facebook page, it has inevitably occurred:

"At this time, BLACK SABBATH will perform only one show of this summer's previously scheduled European tour. It will take place Sunday, June 10 at the U.K.'s Download Festival."

That's not to say members of the band won't be doing shows-- they will simply not be with Iommi:

"So as not to let the promoters and fans down, Ozzy Osbourne will now perform the majority of the previously scheduled BLACK SABBATH dates (both festival performances and the headlining shows) billed as OZZY & FRIENDS. These 'first ever' OZZY & FRIENDS shows will feature appearances by 'special guest' musicians including Official Geezer Butler (who will join Ozzy for a special BLACK SABBATH set as a show of respect and support to their friend, Tony Iommi) and longtime former OZZY band member Zakk Wylde. In addition, OZZY will be accompanied by longtime collaborator and friend Slash at select shows, with other 'special guests' set to join the tour at various stops along the way."

Meanwhile, they are reporting that the legendary guitarist is doing well, posting that Iommi "continues to make excellent progress and is looking forward to getting back out on the road."

Iommi turns 64 years old this month.

Source: Facebook

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap